Tirzepatide for muscle and vessel health in older adults
Treatments studied
Part of Brain & nervous system, Hormones & metabolism clinical trials.
This study tests if the drug tirzepatide can improve muscle and blood vessel health in older adults with obesity. You may be eligible if you are 50 or older, have a BMI between 30 and 40, and do not have diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 50 years old or older
- Your body mass index (BMI) is between 30 and 40
- You do not have diabetes or take any glucose-lowering medication
- You do not have moderate to severe acid reflux (heartburn)
- You do not have stage 4 kidney disease, a personal or family history of certain thyroid cancers, or certain other conditions
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether tirzepatide, a medication for weight management, affects muscle health in women with obesity. It may help if you are looking for a treatment that preserves muscle while losing weight.
This Phase 2 study tests whether tirzepatide can improve how your body handles fat (especially in people with overweight or obesity) and reduce fat-related “lipotoxicity.” It may help with body fat function and related health markers, but you must meet specific health and medication rules.
This trial tests the weight‑loss medication tirzepatide (Mounjaro) in people who are overweight or have obesity and have stable coronary artery disease. The goal is to see if tirzepatide can reduce dangerous fatty plaque in heart arteries.
This study tests whether combining a newer weight-loss medication (tirzepatide) with a structured exercise program helps improve muscle strength and function in people who are overweight or obese. Researchers will measure changes in muscle quality and physical fitness over time.
This trial tests a medicine called tirzepatide, given as an injection, to see if it can improve daily function and symptoms in people with a weak heart (heart failure with reduced ejection fraction) who also have obesity. Tirzepatide works on two natural hormones to help with weight and may also improve heart health.
This study tests if tirzepatide helps people with obesity lose weight, whether or not they have type 2 diabetes. It aims to see how safe and effective the drug is.
Hear when a new Obesity Prevention trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.